Facial erythema after the treatment of dupilumab in SLE patient

BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Dong Hyek, Lee, Jae In, Bae, Joo Yoon, Jung, Hye Jung, Park, Mi Yeon, Ahn, Jiyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491356/
https://www.ncbi.nlm.nih.gov/pubmed/32944024
http://dx.doi.org/10.1186/s13223-020-00458-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491356/
https://www.ncbi.nlm.nih.gov/pubmed/32944024
http://dx.doi.org/10.1186/s13223-020-00458-6

Ejemplares similares